Research Protocol

Retatrutide 30mg — Research Protocol

Dosage Calculator → How to Reconstitute →

Retatrutide — 30mg protocol. Edit the doses below for the 30mg vial.

Quickstart Highlights

Retatrutide is an investigational triple-receptor agonist peptide (targets GLP-1, GIP, and glucagon receptors) under development for obesity and type 2 diabetes[1][2]. Phase 2 trials demonstrated remarkable weight-loss efficacy, with patients losing up to 24% of body weight at 48 weeks on higher doses[3][4]. This educational protocol presents a once-weekly subcutaneous approach with gradual titration to minimize gastrointestinal side effects.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
  • Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
  • Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks.

Dosing & Reconstitution Guide

Phase Dose Units (per injection)
Weeks 1–4 2 mg (2000 mcg) 20 units (0.20 mL) 1 vial per dose
Weeks 5–8 4 mg (4000 mcg) 40 units (0.40 mL) 1 vial per dose
Weeks 9–12 6 mg (6000 mcg) 60 units (0.60 mL) 1 vial per dose
Weeks 13+ 8 mg (8000 mcg) 80 units (0.80 mL) 1 vial per dose

 

Frequency: Inject once weekly subcutaneously[1][2]. All doses ≤12 mg can be drawn from one reconstituted 30 mg vial, making this an efficient vial size for complete protocols. Volumes >1.0 mL may be split into 2 separate subcutaneous injections at different sites to ensure proper absorption[5].

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 4 weeks of reconstitution[16].

Advanced / Aggressive Protocol (3 mL = ~10.0 mg/mL)

Phase Weekly Dose Units (per injection) (mL) Vials Needed
Weeks 1–4 2 mg (2000 mcg) 20 units (0.20 mL) 1 vial per dose
Weeks 5–8 4 mg (4000 mcg) 40 units (0.40 mL) 1 vial per dose
Weeks 9–12 8 mg (8000 mcg) 80 units (0.80 mL) 1 vial per dose
Weeks 13+ 12 mg (12000 mcg) 120 units (1.20 mL) 1 vial per dose

Note: The 12 mg dose represents the highest dose tested in Phase 2 trials[3][4], producing maximum weight-loss efficacy (~24% body weight at 48 weeks). All doses ≤12 mg can be drawn from one reconstituted 30 mg vial. Volumes >1.0 mL should be split into 2 injections at separate sites. Gradual titration is critical to minimize gastrointestinal side effects[6].


Supplies Needed

Plan based on a 12–24 week weekly protocol with gradual titration.

  • Peptide Vials (Retatrutide, 30 mg each):
    • 12 weeks (Standard to 6 mg): 2 vials
    • 24 weeks (Standard to 8 mg): 5 vials
    • 12 weeks (Aggressive to 8 mg): 2 vials
  • Insulin Syringes (U-100, 1 mL capacity):
    • Per week: 1–2 syringes (depending on dose; higher doses require split injections)
    • 12 weeks: 12–24 syringes
    • 24 weeks: 24–48 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
    • 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 24 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for each injection site.
    • Per week: 2–4 swabs (1 per vial + 1–2 per injection site)
    • 12 weeks: ~50 swabs → recommend 1 × 100-count box
    • 24 weeks: ~100 swabs → recommend 1 × 100-count box

Protocol Overview

Protocol Overview

Concise summary of the once-weekly regimen.

  • Goal: Support significant weight reduction and metabolic improvements through triple-receptor activation[1][7].
  • Schedule: Weekly subcutaneous injections for 12–48 weeks (clinical trials ranged 36–48 weeks)[2].
  • Dose Range: 2–12 mg weekly with gradual 4-week titration steps[3][4].
  • Reconstitution: 3.0 mL per 30 mg vial (~10.0 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) for up to 4 weeks[16].

Dosing Protocol

Suggested weekly titration approach from clinical trials.

  • Start: 2 mg weekly for 4 weeks to assess tolerance[6].
  • Escalate: Increase by 2–4 mg every 4 weeks as tolerated.
  • Target: 6–8 mg weekly (standard); 12 mg weekly (advanced/aggressive).
  • Frequency: Once per week (subcutaneous), same day each week.
  • Cycle Length: Minimum 24 weeks; trials extended to 48 weeks[3][4].
  • Timing: Any consistent day/time; rotate injection sites with each dose.

Storage Instructions

Proper storage preserves peptide quality and stability.

  • Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; stable for up to 24 months[16].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks[16].
  • Allow vials to reach room temperature before opening to reduce condensation.
  • For extended storage, aliquot reconstituted solution and freeze at −20 °C (−4 °F); thaw only once before use[17].

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container[14].
  • Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and lipohypertrophy[13].
  • For volumes >1.0 mL, split into 2 separate injections at different sites for better absorption[5].
  • Inject slowly; wait a few seconds before withdrawing the needle to ensure full dose delivery.
  • Document weekly dose, date, and injection sites to maintain consistency.
  • Gradual titration is essential to minimize gastrointestinal side effects; never skip escalation steps[6].

How It Works

Retatrutide’s unique mechanism of action stems from its triple-agonist design. By activating GLP-1 and GIP receptors, it enhances insulin secretion (when glucose is present) and suppresses appetite, similar to existing incretin therapies[7][8]. Additionally, Retatrutide’s glucagon receptor agonism raises metabolic rate and promotes energy expenditure, further amplifying fat burning and weight loss beyond GLP-1/GIP effects alone[7]. The peptide is engineered with a fatty-acid moiety to extend its circulation time (half-life ~6 days), allowing for once-weekly dosing[2]. The combined hormonal activation leads to reduced calorie intake, increased satiety, and enhanced lipid oxidation, yielding potent weight loss and glycemic control[8][9]. Preclinical studies confirmed that adding glucagon activity helps counteract the body’s adaptive slowing of metabolism during weight loss[7]. In essence, Retatrutide tackles three metabolic pathways at once, resulting in greater efficacy in lowering blood glucose and body fat than single- or dual-agonist therapies.

Potential Benefits & Side Effects

Observations from Phase 2 human clinical trials.

Benefits

  • Exceptional weight loss: Patients with obesity (without diabetes) lost an average of 22–24% of body weight at 48 weeks on 8–12 mg doses[3][4].
  • Glycemic control: In type 2 diabetes patients, HbA1c dropped by 1.3–2.0% (from ~8.0% to ~6.0%) with 4–12 mg doses[1]; ~82% reached HbA1c ≤6.5%.
  • Cardiometabolic improvements: Reductions in blood pressure, LDL cholesterol, waist circumference, and liver fat content (>80% resolution of hepatic steatosis on high doses)[10][11].
  • Universal response: 100% of participants on 8–12 mg achieved at least 5% weight reduction[4].

Side Effects

  • Gastrointestinal symptoms: Most common adverse effects were mild-to-moderate nausea, vomiting, and diarrhea, occurring primarily during dose escalation[6][12].
  • Side effects were dose-dependent and transient; gradual titration (4-week intervals) significantly reduced GI discomfort compared to rapid escalation[6].
  • No severe hypoglycemia or serious treatment-related adverse events reported in trials[1][2].
  • Safety profile comparable to GLP-1 agonists when properly titrated[12].

Lifestyle Factors

Complementary strategies for optimal metabolic outcomes.

  • Maintain a balanced, protein-forward diet with adequate micronutrients to support lean mass during weight loss.
  • Combine resistance training (2–3×/week) with regular aerobic activity to preserve muscle and enhance metabolic adaptations.
  • Prioritize sleep (7–9 hours) and stress management to support adherence and hormonal balance.
  • Stay well-hydrated and monitor for signs of dehydration, especially during GI side effects.
  • Work with healthcare providers to monitor metabolic markers (HbA1c, lipids, liver function) throughout the protocol.

Lifestyle Factors

Complementary strategies for optimal metabolic outcomes.

  • Maintain a balanced, protein-forward diet with adequate micronutrients to support lean mass during weight loss.
  • Combine resistance training (2–3×/week) with regular aerobic activity to preserve muscle and enhance metabolic adaptations.
  • Prioritize sleep (7–9 hours) and stress management to support adherence and hormonal balance.
  • Stay well-hydrated and monitor for signs of dehydration, especially during GI side effects.
  • Work with healthcare providers to monitor metabolic markers (HbA1c, lipids, liver function) throughout the protocol.

References

For laboratory and research use only. Minimum 98% purity. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. This protocol is provided for educational and research purposes only and is not medical advice. The purchaser accepts full responsibility for safe handling, storage and lawful use.